Androgenic Alopecia TH07 Clinical Trial

Recruiting Phase 3 Interventional Study
Androgenic Alopecia
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 49
Sex
Male
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
420 (estimated)
Sponsor
Triple Hair Inc · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treat…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Males, 18 to 49 years of age on the date of enrollment. * Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale. * Body Mass Index (BMI) in the range of 19 to 35 kg/m2. * Not administered any systemic or topical treatment for AGA during the …
Contacts

Edouard AL-Chami

647-453-3253

ealchami@triplehair.ca

CONTACT

Lori Hebert

lhebert@triplehair.ca

CONTACT